Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone353-1772-8000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.09 billion
Profitability
Miscellaneous
Employees2,300
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable
Alkermes (NASDAQ:ALKS) Frequently Asked Questions
What is Alkermes' stock symbol?
Alkermes trades on the NASDAQ under the ticker symbol "ALKS."
How were Alkermes' earnings last quarter?
Alkermes Plc (NASDAQ:ALKS) issued its quarterly earnings results on Thursday, February, 14th. The company reported $0.34 EPS for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.39. The company earned $316 million during the quarter, compared to analysts' expectations of $255.71 million. Alkermes had a negative return on equity of 0.49% and a negative net margin of 12.73%. The firm's revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.31 EPS. View Alkermes' Earnings History.
When is Alkermes' next earnings date?
What guidance has Alkermes issued on next quarter's earnings?
Alkermes updated its FY19 earnings guidance on Thursday, February, 14th. The company provided earnings per share guidance of $0.25-0.43 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.64. The company issued revenue guidance of $1.14-1.19 billion, compared to the consensus revenue estimate of $1.10 billion.Alkermes also updated its FY 2019 guidance to $0.25-0.43 EPS.
What price target have analysts set for ALKS?
13 Wall Street analysts have issued twelve-month price objectives for Alkermes' stock. Their forecasts range from $26.00 to $63.00. On average, they anticipate Alkermes' stock price to reach $44.8333 in the next year. This suggests a possible upside of 28.1% from the stock's current price. View Analyst Price Targets for Alkermes.
What is the consensus analysts' recommendation for Alkermes?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 3 sell ratings, 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.
What are Wall Street analysts saying about Alkermes stock?
Here are some recent quotes from research analysts about Alkermes stock:
- 1. According to Zacks Investment Research, "Alkermes' Vivitrol and Aristada continue to drive growth for the company. The company also raised its revenue and earnings guidance for 2018. This year, Alkermes’ development pipeline will witness key events like the upcoming regulatory interactions for ALKS 5461 for the adjunctive treatment of major depressive disorder. The Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee jointly voted that the benefit-risk profile was not adequate to support approval of ALKS 5461. The launch of Aristada Initio during the third quarter has been encouraging. It further distinguishes the company’s position in the market and provides an opportunity to address unmet patient need. However, Alkermes is highly dependent on manufacturing and/or royalty revenue. Estimates have reduced ahead of the Q4 results. The company has positive earnings surprise in the last few quarters." (1/29/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate the Neutral rating for ALKS stock and are reducing our PT by $5 to $41. We believe the FDA advisory panel view of the ALKS-5461 NDA is a major setback not only for the drug but also to the ability of ALKS to convince investors that the company can develop proprietary therapies of meaningful commercial potential." (11/5/2018)
Has Alkermes been receiving favorable news coverage?
News headlines about ALKS stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alkermes earned a news sentiment score of 1.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Alkermes' key competitors?
Some companies that are related to Alkermes include Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Mylan (MYL), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ) and SAGE Therapeutics (SAGE).
What other stocks do shareholders of Alkermes own?
Who are Alkermes' key executives?
Alkermes' management team includes the folowing people:
- Mr. Richard F. Pops, Chairman & CEO (Age 57)
- Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)
- Mr. James M. Frates, Sr. VP, CFO & Treasurer (Age 52)
- Mr. James A. Robinson Jr., Pres & COO (Age 49)
- Mr. Iain Michael Brown, Sr. VP of Fin. & Chief Accounting Officer (Age 50)
Who are Alkermes' major shareholders?
Alkermes' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (10.24%), BlackRock Inc. (6.48%), First Trust Advisors LP (1.45%), Geode Capital Management LLC (1.00%), Geode Capital Management LLC (0.99%) and Thornburg Investment Management Inc. (0.79%). Company insiders that own Alkermes stock include David W Anstice, Elliot Ehrich, Floyd E Bloom, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Laurie Keating, Mark Stejbach, Michael J Landine, Nancy Wysenski, Paul J Mitchell, Richard F Pops and Shane Cooke. View Institutional Ownership Trends for Alkermes.
Which major investors are selling Alkermes stock?
ALKS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bank of New York Mellon Corp, Meditor Group Ltd, Rhenman & Partners Asset Management AB, Bank of America Corp DE, Los Angeles Capital Management & Equity Research Inc., Royal London Asset Management Ltd. and KBC Group NV. Company insiders that have sold Alkermes company stock in the last year include David W Anstice, Floyd E Bloom, James M Frates, Michael J Landine, Paul J Mitchell and Richard F Pops. View Insider Buying and Selling for Alkermes.
Which major investors are buying Alkermes stock?
ALKS stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Two Sigma Investments LP, Canada Pension Plan Investment Board, First Manhattan Co., Korea Investment CORP, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP and Two Sigma Advisers LP. View Insider Buying and Selling for Alkermes.
How do I buy shares of Alkermes?
Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alkermes' stock price today?
One share of ALKS stock can currently be purchased for approximately $35.01.
How big of a company is Alkermes?
Alkermes has a market capitalization of $5.46 billion and generates $1.09 billion in revenue each year. The company earns $-139,310,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Alkermes employs 2,300 workers across the globe.
What is Alkermes' official website?
How can I contact Alkermes?
Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]s.com.
MarketBeat Community Rating for Alkermes (NASDAQ ALKS)
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
